2상모집 중단 (진행 중)

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

연구 개요

This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment

스폰서: 협력: BMS
적응증: Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, Urinary Bladder Diseases, Male Urogenital Diseases, Urinary Bladder Neoplasm, Antineoplastics Toxicity
중재: Nivolumab, Relatlimab
목표 등록: 90명
시작일: 2024-02-19
완료(예정): 2028-08-01
등록번호: NCT06237920 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.